Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 7/20 | 0.47 |
| ▸ | CNR1 | P21554 | 5/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23809528 | 0.90 | PDE4A (0.48) | SLC22A12PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23809210 | 0.84 | HSP90AA1 (0.41) | SLC22A12PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23809277 | 0.81 | SLC22A12 (0.47) | SLC22A12CNR2CNR1 | |
| SCHEMBL23809337 | 0.81 | SLC22A12 (0.47) | SLC22A12CNR2CNR1HRH3 | |
| SCHEMBL23809362 | 0.79 | SLC22A12 (0.67) | SLC22A12 | |
| SCHEMBL26581392 | 0.74 | PDE4A (0.63) | PDE4APDE4BPDE4CPDE4DCNR2 | |
| SCHEMBL30622560 | 0.73 | HTR7 (0.51) | KDM5AKDM5B | |
| SCHEMBL1751729 | 0.73 | HTR7 (0.51) | KDM5AKDM5B | |
| SCHEMBL17122117 | 0.73 | CNR2 (0.47) | CNR2CNR1KDM5AKDM5B | |
| SCHEMBL15681588 | 0.73 | HDAC3 (0.63) | CNR2CNR1KDM5AKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | SLC22A12 3136/4885PDE4A 3812/4885PDE4B 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.